As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...Read More
Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain.
“It is very unusual for a startup or even a mid-sized biotech company to have four different medications in clinical development for pain relief,” Dr. Eliseo Salinas, president and CSO, says in an interview with BioTuesdays.com.
“Our robust portfolio includes three products that combine proven drug candidates with novel delivery methods to create new drugs for new indications, while our fourth is a new entity, which offers significant upside,” he points out. “We target every level of the chronic pain spectrum.”Read More